Hydroquinone-Free Options for Melasma: What Has Evidence?

People who want to avoid hydroquinone usually ask the same question: what else has evidence behind it? Among the non-hydroquinone options discussed in the cited reviews are cysteamine and azelaic acid, and daily light protection sits underneath both. Kojic acid, oral tranexamic acid, and in-office procedures come up too, though the evidence and the safety needs differ for each. What follows is what the studies found. It isn't a plan for you, and your plan should come from a dermatologist who has looked at your skin.

Melasma causes brown or gray-brown patches, usually on the face. Hydroquinone has anchored melasma care for decades.

Why do people want to skip hydroquinone?

Irritation is one reason people discuss alternatives. A 2023 analysis of melasma treatments found skin irritation in 50.9% of people using hydroquinone combination creams, the highest pooled estimate of any group in the analysis.

Most articles stop there. Here's the rest. The same analysis reported a pooled irritation estimate of 42.2% for cysteamine studies. That estimate came from separate studies and is not a head-to-head safety comparison with hydroquinone.

The experts have weighed in too. In a 2025 international consensus, 38 dermatologists from 11 countries went through three rounds of voting and landed on 21 statements with broad agreement behind them. That panel called supervised hydroquinone triple combination creams the gold standard and listed azelaic acid, kojic acid, and oral tranexamic acid as alternatives. The publication reports grant support from Galderma India.

Which topicals have real evidence?

Cysteamine. A 2024 analysis pooled seven randomized trials of 5% cysteamine cream. The pooled estimate favored 5% cysteamine versus placebo on melasma scores. Against 4% hydroquinone, the pooled analysis did not detect a statistically significant difference. Redness, irritation, burning, itching, and dryness were more common than with placebo, and the analysis did not detect a statistically significant difference versus hydroquinone.

A 2026 analysis went further. It combined five trials covering 193 patients, 97 of them on 5% cysteamine and the rest on hydroquinone. The review did not detect a statistically significant difference in the modified Melasma Area and Severity Index (mMASI) outcome. Its abstract also prints two figures, 37 for cysteamine and 39 for hydroquinone, next to that comparison. It does not identify those figures as patient counts, so I am not treating them as group sizes. The review also did not detect statistically significant differences in redness, burning, or itching. The authors, who reported no company ties, called cysteamine comparable to hydroquinone in the short term and flagged the small evidence base and short follow-up as limits.

Azelaic acid. A 2023 analysis of six trials covering 673 patients compared 20% azelaic acid with hydroquinone, at 4% in five trials and 2% in one, over 8 to 24 weeks. One of the pooled trials also gave oral tranexamic acid to both groups, which muddies its contribution. Azelaic acid came out slightly ahead on melasma scores. Everything else, including side effects, showed no clear difference. The authors kept it careful: azelaic acid may be better, and bigger studies with longer follow-up are needed.

How the classes were analyzed. The 2023 analysis measured how much each ingredient class improved scores from start to finish. These before-and-after estimates came from different studies and cannot establish that one ingredient class is more effective or safer than another. The pooled irritation estimates were 42.2% for cysteamine, 18.7% for azelaic acid, 5.3% for kojic acid, and 0.8% for tranexamic acid.

These trials tested other formulas, generally at 5% where the strength was reported. Illuminate Rx is labeled 10%. My search found no PubMed-indexed paper or ClinicalTrials.gov record through August 16, 2026 that names Illuminate Rx, tests this finished 10% formula, or compares it with a 5% cream. A higher concentration does not prove greater benefit.

Why daily light protection comes first

The 2025 consensus is blunt about it. Broad-spectrum sunscreen is essential in melasma care. It's the foundation of every plan, hydroquinone-free or not, and you don't need a prescription for it.

Illuminate Rx directions call for broad-spectrum sun protection factor (SPF) 30 or higher during the day. The steps are on the how-to-use page.

What needs a dermatologist

Some of these are never do-it-yourself:

• Oral tranexamic acid. The consensus names it as an alternative, but it's a pill. Only a clinician can decide whether it fits you and watch how you do on it.
• Hydroquinone triple combination creams. Regulated, supervised, and still the gold standard.
• Chemical peels and microneedling. In-office add-ons, not replacements for topical care.
• Lasers. The consensus holds these back for melasma that hasn't responded to anything else.

An article can't diagnose you. New, changing, bleeding, or painful spots need an in-person exam.

How to read the evidence yourself

Check what's being compared. Some numbers show how much one group improved from start to finish. Only head-to-head trials tell you whether one ingredient beat another.

Check the size. The azelaic-acid review covered 673 patients. The cysteamine-versus-hydroquinone review covered 193 patients across five trials, with 97 receiving cysteamine. That is still a limited evidence base for a broad treatment comparison.

Check who is endorsing what. The 2025 consensus names azelaic acid, kojic acid, and oral tranexamic acid. Its published abstract doesn't mention cysteamine, so nobody should be quoting it as a cysteamine endorsement.

Check safety alongside results. Cysteamine's 42.2% irritation rate belongs in the same sentence as its efficacy numbers.

Next step

Read the studies linked below and in the research library, and look over the application steps on the how-to-use page. For a diagnosis, a prescription, oral tranexamic acid, or any procedure, see a board-certified dermatologist.